JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

42.24 4.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

39.47

Max

43.17

Belangrijke statistieken

By Trading Economics

Inkomsten

-547M

-179M

Verkoop

-515M

28M

Winstmarge

-643.397

Werknemers

609

EBITDA

-546M

-148M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+5.31% upside

Dividenden

By Dow Jones

Volgende Winsten

25 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.2B

5.5B

Vorige openingsprijs

37.3

Vorige sluitingsprijs

42.24

Nieuwssentiment

By Acuity

90%

10%

28 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2025, 23:32 UTC

Populaire aandelen

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 okt 2025, 23:02 UTC

Winsten

AIA Group 3Q Value of New Business Grew

30 okt 2025, 23:45 UTC

Marktinformatie

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 okt 2025, 23:00 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 okt 2025, 22:56 UTC

Marktinformatie

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 okt 2025, 22:31 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 okt 2025, 22:29 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q EPS 66c >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Rev $431M >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Net $179M >BVN

30 okt 2025, 22:16 UTC

Marktinformatie
Winsten

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 okt 2025, 22:14 UTC

Winsten

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 okt 2025, 22:00 UTC

Winsten
Acquisities, Fusies, Overnames

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 okt 2025, 21:39 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:26 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:14 UTC

Marktinformatie
Winsten

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 okt 2025, 21:04 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold Skouries on Track for 1Q of 2026

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Adj EPS 41c >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Rev $434.7M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Net $56M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q EPS 27c >EGO

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

5.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 42.43 USD  5.31%

Hoogste 80 USD

Laagste 17 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

28 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat